A recent experiment with a drug has proven to be beneficial as it is exhibiting promise against a severe terminal eye disease that is known for blinding old age people. Very intriguingly, it has been observed that the drug works in patients who have a specific gene flaw that damages their ability to see. Age-related macular degeneration or AMD is the major cause of loss of vision among the senior population, thus slowly eroding the central vision. There are several types of this ailment, but the dominant type is the advanced type known as “dry” macular degeneration that cannot be treated. Over 5 million people across the world suffer from this type. Initially the patient might notice blurriness at the time when they look right straight ahead. Ultimately, many of them develop blank spots and become blind.
What does the drug do?
Lampalizumab, an experimental drug, focuses to inhibit the obliteration of light sensing cells in the eye retina, creeping lesion that classify the dry AMD stage known as “geographic atrophy.’ As these cells cannot grow back, their complete destruction causes irreversible vision loss. The research and trial thus found that when the patients were given monthly injection of the drug in the eye, the drug self-effacingly slowed the worsening of the ailment in comparison to patients who were given just dummy shots. What came as a surprise was that the patients who carried a genetic flaw that triggered the risk of the degeneration were the ones who were actually being benefitted by the drug. However, the research is in its initial stage to come to any conclusion at this time.